Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent
1998
Inhibition of Cytochrome P450 by JM216, an Oral Platinum Agent
publication
Evidence: moderate
Author Information
Author(s): Y Ando, T Shimizu, K Nakamura, T Mushiroda, T Nakagawa, T Kodama, T Kamataki
Primary Institution: Hokkaido University
Hypothesis
Does JM216 inhibit cytochrome P450 enzymes in human liver microsomes?
Conclusion
JM216 shows strong and non-specific inhibitory effects on various cytochrome P450 enzymes.
Supporting Evidence
- JM216 inhibited the catalytic activities of CYP isozymes with IC50 values between 0.3 µM and 10 µM.
- The inhibition occurred in a non-competitive manner.
- Further in vivo studies are needed to confirm the in vitro findings.
Takeaway
JM216, a new oral cancer drug, can block certain enzymes in the liver that help break down other drugs, which might affect how those drugs work.
Methodology
The study measured the inhibition potential of JM216 on various cytochrome P450 enzymes using human liver microsomes.
Limitations
The study is in vitro, and the in vivo effects of JM216 on drug metabolism remain to be confirmed.
Want to read the original?
Access the complete publication on the publisher's website